The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia.
María Nieves Saez PerdomoRuth StuckeyElena González-PérezSantiago Sánchez-SosaPaula Estupiñan-CabreraSunil Lakhwani LakhwaniJosé David González San MiguelNuria Hernanz SolerMarina GordilloGloria González BritoMaría Tapia-TorresAna RuanoAdrián Segura-DíazHugo LuzardoCristina Bilbao-SieyroMaría Teresa Gómez-CasaresPublished in: Hematology reports (2024)
In conclusion, it is important to estimate the cardiovascular risk at the diagnosis of CML as it can help determine whether a patient is likely to develop a VAE during TKI treatment.